Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

[1]  Komal Doshi,et al.  Delayed hypersensitivity reaction to hyaluronic acid dermal filler post‐COVID‐19 viral infection , 2021, Journal of cosmetic dermatology.

[2]  Erica S. Shenoy,et al.  Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 , 2021, The New England journal of medicine.

[3]  T. Shimabukuro,et al.  Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. , 2021, JAMA.

[4]  M. Landau,et al.  “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment” , 2021, Archives of Dermatological Research.

[5]  Chris Baraniuk.  How to vaccinate the world against covid-19 , 2021, BMJ.

[6]  J. A. Cárdenas-de la Garza,et al.  SARS‐CoV‐2 spike protein positivity in pityriasis rosea‐like and urticaria‐like rashes of COVID‐19 , 2021, The British journal of dermatology.

[7]  N. Mesinkovska,et al.  The art of prevention: COVID-19 vaccine preparedness for the dermatologist☆☆☆ , 2021, International Journal of Women's Dermatology.

[8]  Paige G. Wickner,et al.  mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach , 2020, The Journal of Allergy and Clinical Immunology: In Practice.

[9]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[10]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[11]  K. Walker.  SARS-CoV-2 Vaccine , 2020, Global reproductive health.

[12]  J. Rodríguez-Peralto,et al.  SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases , 2020, The British journal of dermatology.

[13]  J. Lipoff,et al.  Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries , 2020, Journal of the American Academy of Dermatology.

[14]  J. Lipoff,et al.  The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries , 2020, Journal of the American Academy of Dermatology.

[15]  C. A. González-Cruz,et al.  Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases , 2020, The British journal of dermatology.

[16]  W. Philipp-Dormston,et al.  Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness , 2019, Clinical, cosmetic and investigational dermatology.

[17]  S. Spector,et al.  Adverse reactions to vaccines practice parameter 2012 update. , 2012, The Journal of allergy and clinical immunology.

[18]  E. Appella,et al.  H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Wynder.  The art of prevention. , 1962, Journal of the American Medical Association (JAMA).

[20]  C. Elmets,et al.  Dermatologic health disparities. , 2012, Dermatologic clinics.

[21]  A. Barbaud,et al.  First case of erythermalgia related to hepatitis B vaccination. , 1999, The Journal of rheumatology.

[22]  S. Padeh,et al.  Erythromelalgia following influenza vaccine in a child. , 1997, Clinical and experimental rheumatology.